EMP2, epithelial membrane protein 2, 2013

N. diseases: 46; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0032580
Disease: Adenomatous Polyposis Coli
Adenomatous Polyposis Coli 		0.010 Biomarker disease BEFREE EMP2 knockdown in APC shRNA cells revealed that APC regulates apical-basal polarity and cyst size through EMP2. 27890644 2017
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma 		0.020 Biomarker disease BEFREE Preclinical studies have demonstrated that EMP2 is associated with disease prognosis in a number of human cancers, including glioblastoma. 28720310 2017
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma 		0.020 Biomarker disease BEFREE Our group previously demonstrated epithelial membrane protein-2 (EMP2) involvement in pathologic angiogenesis in multiple cancer models including breast cancer and glioblastoma. 30646013 2019
CUI: C0033036
Disease: Atrial Premature Complexes
Atrial Premature Complexes 		0.010 Biomarker disease BEFREE Epithelial Membrane Protein 2 and β1 integrin signaling regulate APC-mediated processes. 27890644 2017
CUI: C1263846
Disease: Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder 		0.100 GeneticVariation disease GWASCAT Family-based genome-wide association scan of attention-deficit/hyperactivity disorder. 20732626 2010
CUI: C1263846
Disease: Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder 		0.100 GeneticVariation disease GWASDB Family-based genome-wide association scan of attention-deficit/hyperactivity disorder. 20732626 2010
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE The purpose of this study was to assess the potential of epithelial membrane protein 2 (EMP2) as a novel biomarker for CTC retrieval in breast cancer. 30218306 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE Our group previously demonstrated epithelial membrane protein-2 (EMP2) involvement in pathologic angiogenesis in multiple cancer models including breast cancer and glioblastoma. 30646013 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.010 Biomarker disease BEFREE EMP2 gene silencing and stable lung cancer cell lines established using EMP2 lentiviral shRNA induced K8 phosphorylation and reorganization. 26876307 2016
CUI: C0007138
Disease: Carcinoma, Transitional Cell
Carcinoma, Transitional Cell 		0.010 Biomarker disease BEFREE EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy. 23838430 2013
CUI: C0007959
Disease: Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease 		0.010 Biomarker disease LHGDN Mapping of Charcot-Marie-Tooth disease type 1C to chromosome 16p identifies a novel locus for demyelinating neuropathies. 11713717 2002
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.020 Biomarker disease BEFREE Preclinical studies have demonstrated that EMP2 is associated with disease prognosis in a number of human cancers, including glioblastoma. 28720310 2017
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.020 Biomarker disease BEFREE Our group previously demonstrated epithelial membrane protein-2 (EMP2) involvement in pathologic angiogenesis in multiple cancer models including breast cancer and glioblastoma. 30646013 2019
CUI: C0085109
Disease: Corneal Neovascularization
Corneal Neovascularization 		0.010 Biomarker disease BEFREE In this paper, we investigate the efficacy of anti-EMP2 immunotherapy in the prevention of corneal neovascularization. 30646013 2019
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma 		0.020 AlteredExpression disease BEFREE The residualizing agent, (64)Cu-DOTA anti-EMP2 minibody, achieved high uptake in endometrial cancer xenografts overexpressing EMP2 (10.2 ± 2.6, percent injected dose per gram (%ID/g) ± SD) with moderate uptake in wild-type HEC1A tumors (6.0 ± 0.1). 22585360 2013
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma 		0.020 Biomarker disease BEFREE Our results collectively suggest that anti-EMP2 therapy may be a novel method of reducing endometrial cancer stem cells. 28604744 2017
CUI: C0014170
Disease: Endometrial Neoplasms
Endometrial Neoplasms 		0.020 Biomarker group BEFREE Following conjugation to DOTA (1,4,7,10-tetraazacyclododecane-N,N',N',N'″-tetraacetic acid), the minibody was radiolabeled with (64)Cu (t (1/2) = 12.7 h) and evaluated in mice as a positron emission tomography (PET) imaging agent for human EMP2-expressing endometrial tumor xenografts. 22585360 2013
CUI: C0014170
Disease: Endometrial Neoplasms
Endometrial Neoplasms 		0.020 Biomarker group LHGDN Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. 19010852 2008
CUI: C0339543
Disease: Epiretinal Membrane
Epiretinal Membrane 		0.010 AlteredExpression disease BEFREE Proliferative vitreoretinopathy-induced membranes (all causes) showed greater expression of EMP2 than ERMs with higher SI (1.81 vs. 1.38; P = 0.07) and PP (2.08 vs. 1.54; P = 0.09). 27294805 2016
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation 		0.010 Biomarker phenotype BEFREE EMP2 was significantly reduced in both villous and extravillous trophoblast populations in IUGR placentas. 28295343 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.040 Biomarker disease BEFREE Our group previously demonstrated epithelial membrane protein-2 (EMP2) involvement in pathologic angiogenesis in multiple cancer models including breast cancer and glioblastoma. 30646013 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.040 Biomarker disease BEFREE Preclinical studies have demonstrated that EMP2 is associated with disease prognosis in a number of human cancers, including glioblastoma. 28720310 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.040 Biomarker disease BEFREE Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. 28597184 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.040 AlteredExpression disease BEFREE The percentage of samples with high EMP2 expression was greater in GBMs than lower grade gliomas (90.0 vs. 52.6%, P = 0.001). 28887715 2018
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.040 Biomarker disease BEFREE Preclinical studies have demonstrated that EMP2 is associated with disease prognosis in a number of human cancers, including glioblastoma. 28720310 2017